[go: up one dir, main page]

AU2002241533A1 - Cytonkine receptor zcytor19 - Google Patents

Cytonkine receptor zcytor19

Info

Publication number
AU2002241533A1
AU2002241533A1 AU2002241533A AU4153302A AU2002241533A1 AU 2002241533 A1 AU2002241533 A1 AU 2002241533A1 AU 2002241533 A AU2002241533 A AU 2002241533A AU 4153302 A AU4153302 A AU 4153302A AU 2002241533 A1 AU2002241533 A1 AU 2002241533A1
Authority
AU
Australia
Prior art keywords
polypeptides
zcytor19
receptor
methods
vitro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002241533A
Inventor
Francis J Grant
Julia E. Novak
Scott R. Presnell
Theodore E. Whitmore
Wen-Feng Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of AU2002241533A1 publication Critical patent/AU2002241533A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)

Abstract

Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor19, a novel class II cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor19, are located on chromosome 1p36.11, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
AU2002241533A 2000-11-28 2001-11-28 Cytonkine receptor zcytor19 Abandoned AU2002241533A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25356100P 2000-11-28 2000-11-28
US60/253,561 2000-11-28
US26721101P 2001-02-07 2001-02-07
US60/267,211 2001-02-07
PCT/US2001/044808 WO2002044209A2 (en) 2000-11-28 2001-11-28 Cytonkine receptor zcytor19

Publications (1)

Publication Number Publication Date
AU2002241533A1 true AU2002241533A1 (en) 2002-06-11

Family

ID=26943370

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002241533A Abandoned AU2002241533A1 (en) 2000-11-28 2001-11-28 Cytonkine receptor zcytor19

Country Status (12)

Country Link
US (10) US20030027253A1 (en)
EP (1) EP1356046B1 (en)
JP (1) JP2004532611A (en)
AT (1) ATE445701T1 (en)
AU (1) AU2002241533A1 (en)
CA (1) CA2430485A1 (en)
CY (1) CY1110921T1 (en)
DE (1) DE60140213D1 (en)
DK (1) DK1356046T3 (en)
ES (1) ES2334888T3 (en)
PT (1) PT1356046E (en)
WO (1) WO2002044209A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1356046B1 (en) 2000-11-28 2009-10-14 ZymoGenetics, L.L.C. Cytokine receptor zcytor19
TW200300170A (en) * 2001-11-09 2003-05-16 Wyeth Corp Type 2 cytokine receptor and nucleic acids encoding same
US7033787B2 (en) * 2001-12-21 2006-04-25 Ludwig Institute For Cancer Research Isolated cytokine receptor LICR-2
US20040029228A1 (en) * 2002-04-19 2004-02-12 Presnell Scott R. Cytokine receptor
US20040170982A1 (en) * 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
US20060246161A1 (en) * 2003-02-21 2006-11-02 Hongtao Xing Method of making medicament for treating anemia
DK1668031T3 (en) 2003-08-07 2008-06-30 Zymogenetics Inc Homogeneous Preparations of IL-29
WO2005087810A2 (en) 2004-03-08 2005-09-22 Zymogenetics, Inc. Dimeric fusion proteins and materials and methods for producing them
EP2389944A1 (en) 2004-07-29 2011-11-30 ZymoGenetics, L.L.C. Use of IL-28 and IL-29 to treat cancer
KR101370280B1 (en) 2005-07-26 2014-03-06 바이알 - 포르텔라 앤드 씨에이 에스에이 Nitrocatechol Derivatives as COMT Inhibitors
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
JP5517629B2 (en) 2007-01-31 2014-06-11 ノヴィファーマ，エス．アー． Dosing schedule for COMT inhibitors
WO2009058888A1 (en) * 2007-10-31 2009-05-07 The Scripps Research Institute Combination therapy to treat persistent viral infections
RU2701731C2 (en) 2009-04-01 2019-10-01 Биал-Портела Энд Ка, С.А. Pharmaceutical preparations containing nitro catechine derivatives, and methods for preparing thereof
DK2413913T3 (en) * 2009-04-01 2022-06-13 Bial Portela & Ca Sa PHARMACEUTICAL FORMULATIONS INCLUDING NITROCATE CHOLD DERIVATIVES AND MANUFACTURING METHODS
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
CN103732610A (en) * 2011-06-13 2014-04-16 默沙东公司 Methods of purification of native or mutant forms of diphtheria toxin
BR112014014341A2 (en) 2011-12-13 2017-08-22 Bial Portela & Ca Sa METHYL INTERMEDIATE, ITS PREPARATION METHOD AND USES, AND PHARMACEUTICAL COMPOSITION
SG10201800313UA (en) * 2013-03-15 2018-02-27 Abbvie Inc Antibody drug conjugate (adc) purification
US9416181B2 (en) 2013-05-06 2016-08-16 Abbvie Inc. Compositions for cell culture and methods of using the same
WO2016033509A1 (en) * 2014-08-29 2016-03-03 The Regents Of The University Of Colorado, A Body Corporate Aquaporin-4 antibodies and uses thereof for the treatment of neuromyelitis optica
WO2016083863A1 (en) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease
EP3442567B1 (en) * 2016-04-13 2025-12-03 Orimabs Ltd. Anti-psma antibodies and use thereof
US20250129132A1 (en) * 2021-09-21 2025-04-24 University Of Washington Genetically encoded and exogenously triggered protein-protein ligation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5945511A (en) * 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
AU6069300A (en) 1999-07-02 2001-01-22 Chiron Corporation Novel human genes and gene expression products
ATE549347T1 (en) * 2000-09-08 2012-03-15 Schering Corp MAMMAL GENES, AND ASSOCIATED REAGENTS, METHODS
EP1356046B1 (en) * 2000-11-28 2009-10-14 ZymoGenetics, L.L.C. Cytokine receptor zcytor19
JP4350950B2 (en) * 2001-04-20 2009-10-28 ザイモジェネティクス，インコーポレイティド Family of cytokine proteins
WO2003031620A1 (en) 2001-10-02 2003-04-17 Mochida Pharmaceutical Co., Ltd. Novel class ii cytokine receptor
TW200300170A (en) 2001-11-09 2003-05-16 Wyeth Corp Type 2 cytokine receptor and nucleic acids encoding same
US7033787B2 (en) * 2001-12-21 2006-04-25 Ludwig Institute For Cancer Research Isolated cytokine receptor LICR-2
US7820793B2 (en) 2002-02-08 2010-10-26 University Of Medicine And Dentistry Of New Jersey IFN-λ polypeptides and compositions
US20040029228A1 (en) 2002-04-19 2004-02-12 Presnell Scott R. Cytokine receptor
JP2006509041A (en) 2002-10-23 2006-03-16 ザイモジェネティクス，インコーポレイティド Methods for treating viral infections using IL-28 and IL-29
EP1594893A2 (en) 2003-02-14 2005-11-16 Sagres Discovery, Inc. Therapeutic targets in cancer

Also Published As

Publication number Publication date
US20070048799A1 (en) 2007-03-01
US20070117165A1 (en) 2007-05-24
ES2334888T3 (en) 2010-03-17
WO2002044209A3 (en) 2003-08-21
US20070048804A1 (en) 2007-03-01
US20140248661A1 (en) 2014-09-04
WO2002044209A2 (en) 2002-06-06
ATE445701T1 (en) 2009-10-15
JP2004532611A (en) 2004-10-28
DE60140213D1 (en) 2009-11-26
US20120064571A1 (en) 2012-03-15
PT1356046E (en) 2010-03-09
EP1356046B1 (en) 2009-10-14
EP1356046A2 (en) 2003-10-29
CY1110921T1 (en) 2015-06-10
DK1356046T3 (en) 2010-03-01
US20070048846A1 (en) 2007-03-01
US7618791B2 (en) 2009-11-17
US7601809B2 (en) 2009-10-13
US7608452B2 (en) 2009-10-27
US20050266485A1 (en) 2005-12-01
US20030027253A1 (en) 2003-02-06
US20070111942A1 (en) 2007-05-17
CA2430485A1 (en) 2002-06-06
US20110091876A1 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
AU2002241533A1 (en) Cytonkine receptor zcytor19
WO2002000721A3 (en) Cytokine receptor zcytor17
EP1749888A3 (en) Soluble zalpha11 cytokine receptors
NZ510744A (en) Cytokine receptor zalpha11
UA84387C2 (en) Human cytokine as a ligand of zalpha receptor and use thereof
WO2002012345A3 (en) Soluble zcytor 11 cytokine receptors
ATE371735T1 (en) HEMATOPOIETIC CYTOKINE RECEPTOR
EP0821728A4 (en) Tie-2 ligands, methods of making and uses thereof
WO2003060090A3 (en) Novel cytokine zcytor17 ligand
MXPA02002384A (en) Fibroblast growth factor like polypeptides.
EP0907730A4 (en) Haemopoietin receptor and genetic sequences encoding same
IL110672A0 (en) Therapeutic heterocycles
MXPA04000886A (en) DERIVATIVES OF TRIAZOLYL-IMIDAZOPYRIDINE AND OF THE TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2a.
NO971341D0 (en) Promoter for receptor tyrosine kinase TIE
MXPA03000227A (en) Novel compounds.
PT877803E (en) PROTEIN RECEPTOR OB AND COMPOSITIONS AND RELATED METHODS
AU9363398A (en) Hepatitis c receptor protein cd81
DE60117788D1 (en) HUMAN WINGLESS-ENOUGH GENES
UA84540C2 (en) Novel cytokine zcytor17 ligand